metformin has been researched along with Familial Nonmedullary Thyroid Cancer in 5 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thyroid cancer is among the most common types of malignant tumor of the endocrine system." | 1.51 | Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo. ( Chen, K; Li, R; Qi, L; Song, S; Ye, J; Zhai, W; Zhou, C, 2019) |
| "Metformin displays both direct and indirect anti-tumor effects." | 1.42 | Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. ( Chiovato, L; Coperchini, F; Magri, F; Pignatti, P; Rotondi, M, 2015) |
| "Oral metformin treatment via drinking water significantly delayed tumor growth in both tumor development model and established tumor models." | 1.40 | Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. ( Cho, SW; Han, SK; Kim, YA; Oh, BC; Park, DJ; Park, YJ; Sun, HJ; Yi, KH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, Y | 1 |
| Feng, C | 1 |
| Kuang, J | 1 |
| Guo, L | 1 |
| Guan, H | 1 |
| Dong, LR | 1 |
| Wang, X | 1 |
| Hu, K | 1 |
| Li, S | 1 |
| Xiong, YJ | 1 |
| Li, M | 1 |
| Tang, H | 1 |
| Liu, AD | 1 |
| Song, XD | 1 |
| Ye, J | 1 |
| Qi, L | 1 |
| Chen, K | 1 |
| Li, R | 1 |
| Song, S | 1 |
| Zhou, C | 1 |
| Zhai, W | 1 |
| Cho, SW | 1 |
| Yi, KH | 1 |
| Han, SK | 1 |
| Sun, HJ | 1 |
| Kim, YA | 1 |
| Oh, BC | 1 |
| Park, YJ | 1 |
| Park, DJ | 1 |
| Rotondi, M | 1 |
| Coperchini, F | 1 |
| Pignatti, P | 1 |
| Magri, F | 1 |
| Chiovato, L | 1 |
5 other studies available for metformin and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Metformin exerts an antitumoral effect on papillary thyroid cancer cells through altered cell energy metabolism and sensitized by BACH1 depletion.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Cell Line, Tumor; Cell Movement; Cell Prolifera | 2022 |
[Effects of metformin on papillary thyroid carcinoma in nude rats model].
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferatio | 2018 |
Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum Chaperone BiP; Endop | 2019 |
Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cells | 2014 |
Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Cell Death; Cell Proliferation; Cells, Cultu | 2015 |